Caplin Point Laboratories Schedules Q4 & FY2026 Earnings Conference Call for May 14, 2026
Caplin Point Laboratories has announced a post-results earnings conference call for May 14, 2026, at 16:30 hrs IST, to discuss Q4 & FY2026 financial performance. The call will be attended by senior management including the Chairman, Vice Chairman, MD, CFO, and Deputy CFO, with dial-in access available across multiple geographies including India, Hong Kong, Singapore, USA, and the UK.
*this image is generated using AI for illustrative purposes only.
Caplin Point Laboratories has announced a post-results earnings conference call scheduled for Thursday, May 14, 2026, at 16:30 hours IST, to discuss the company's financial performance for the quarter and year ended March 31, 2026. The announcement was made on May 07, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Earnings Conference Call Details
The conference call will follow the company's Q4 & FY2026 results announcement and will cover financial results and business outlook. Investors, analysts, and fund houses are invited to participate. The following dial-in details have been provided for the event:
| Parameter: | Details |
|---|---|
| Date: | Thursday, May 14, 2026 |
| Time: | 16:30 hours IST |
| Universal Dial-In: | +91 22 6280 1222 / +91 22 7115 8123 |
| Hong Kong (Toll-Free): | 800 964 448 |
| Singapore (Toll-Free): | 800 101 2045 |
| USA (Toll-Free): | 1 866 746 2133 |
| UK (Toll-Free): | 0 808 101 1573 |
Participants are advised to register in advance using the Diamond Pass link provided in the conference call invitation to ensure timely connectivity.
Management Representatives
The management team scheduled to represent Caplin Point Laboratories during the call includes:
- Mr. C.C. Paarthipan – Chairman
- Mr. Vivek Partheeban – Vice Chairman
- Dr. Sridhar Ganesan – Managing Director
- Mr. D. Murlidharan – Chief Financial Officer
- Mr. Sathya Narayanan M – Deputy CFO
Investor Relations Contact
For any queries related to the earnings conference call, participants may reach out to the designated investor relations contacts:
| Contact: | Details |
|---|---|
| Churchgate Partners (Simran Malhotra / Soham Arora): | +91 99454 72589 |
| Churchgate Partners Email: | caplinpoint@churchgatepartners.com |
| 360 One CM Research (Mrs. Julie Mehta): | +91 22 4031 7000 |
| 360 One CM Research Email: | julie.mehta@bksec.com |
The regulatory filing was signed by Venkatram G, General Counsel & Company Secretary (Membership No. A23989), on behalf of Caplin Point Laboratories. The company has noted that the schedule of the conference call is subject to change due to exigencies on the part of the analyst or the company.
Historical Stock Returns for Caplin Point Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.37% | +9.22% | +15.90% | -3.41% | +0.22% | +223.19% |
How has Caplin Point Laboratories' revenue from emerging markets like Latin America and Africa trended over FY2026, and what growth targets has management set for FY2027?
Will Caplin Point Laboratories provide any guidance on its US FDA-regulated market expansion strategy or new product filings during the Q4 FY2026 earnings call?
How might Caplin Point's FY2026 margins compare to peers given rising API costs and currency fluctuations in key export markets?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
